BLINCYTO 35/38.5 mcg

Blincyto contains Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. Blincyto uses are:

• B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease greater than or equal 0.1%. 
• Relapsed or refractory B-cell precursor ALL (Acute Lymphoblastic Leukemia). 

• Assess patients with blinatumomab injection for signs and symptoms of neurological toxicities. Advise outpatients on Blinatumomab to contact their health specialist if they develop signs/symptoms of neurological toxicities.
• Monitor patients with Blincyto doses for signs and symptoms of infection and treat appropriately.
• Assess laboratory parameters (including, but not limited to, WBC count and absolute neutrophil count) during blinatumomab infusion. Interrupt this medication if prolonged neutropenia occurs.
• Monitor aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and total blood bilirubin before the start of and while on Blincyto 35 mcg treatment.
• Assess patients who develop signs of pancreatitis. Management of pancreatitis may need either temporary interruption or discontinuation of Blincyto injection and dexamethasone. 
• Healthcare professionals recommend not to have vaccination with live virus vaccines for at least before 2 weeks Blinatumomab 35 mcg treatment, during treatment, and until immune recovery following the last cycle of Blinatumomab.

What documents are required to import Blincyto?

Blincyto (Blinatumomab) injection can be imported by patients or government hospitals on behalf of patients. The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s ID proof (issued by the Government of the respective country).

How is the order confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from a doctor.
• Import permit if applicable.

Is Blincyto available worldwide?

Blincyto (Blinatumomab) injection is a prescription pharmaceutical drug that legally requires a medical prescription for dispensation.

Urgent Meds facilitates the import of critical medications like Blincyto (Blinatumomab) globally, ensuring the named patient supply (NPS). Urgent Meds provides essential support for:

• Availability of Blincyto in countries such as Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
• Availability in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Bangalore, Pune, etc.).
• Determining medicine price.
• Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia.
• Ensuring 100% transparency.

Blincyto (Blinatumomab) injection can be made available to patients, doctors, and hospitals in various countries across the globe. The order will be confirmed only after receiving a valid prescription from the doctor and, if required, an import permit.

Urgent Meds can facilitate the supply of Blincyto (prescription medicine) to locations worldwide while adhering to legal requirements (if applicable).

We assure quality and worldwide delivery as per the buyer’s specifications.

Urgent Meds is proficient in sourcing Blincyto (Blinatumomab) (Medicines from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.

What is the Generic Name for the trade name drug Blincyto®?

Blincyto® is the trade name for the drug Blinatumomab.

Is Blincyto® approved by the FDA?

Yes, Blincyto® is approved by the FDA. The date of approval was 2014.

What kind of drug is Blincyto?

Blincyto® is a prescription-only medicine used for treating patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1%, as well as relapsed or refractory B-cell precursor ALL.

What is the dosage and form of Blincyto® available?

Blincyto® is available as 35 mcg of lyophilized powder in a single-use vial for reconstitution.

What are the ingredients in the medicine Blincyto?

The active ingredient in the vials is Blinatumomab. Inactive ingredients include citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, sodium hydroxide, and preservative-free sterile water for injection.

Is Blincyto chemotherapy?

No, Blincyto is an immunotherapy. It is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 on B-lineage cells and CD3 on T cells, helping the immune system to target and destroy cancer cells.

How much does Blincyto® cost in India?

For pricing information on Blincyto in India, please contact Urgent Meds via call or WhatsApp at +1-647-818-4196 or email info@urgentmeds.in.

What is the latest FDA approval for Blincyto?

On June 14, 2024, the FDA approved Blincyto for use in adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase of chemotherapy. This approval allows its use regardless of measurable residual disease (MRD) status.

How effective is Blincyto in the consolidation phase of B-ALL treatment?

Clinical trials, such as the E1910 study, have shown that Blincyto significantly improves overall survival rates when added to a multiphase consolidation chemotherapy regimen. The three-year overall survival was 84.8% for patients receiving Blincyto plus chemotherapy compared to 69% for those on chemotherapy alone.

What makes Blincyto a unique treatment option for B-ALL?

Blincyto is the first and only bispecific T-cell engager (BiTE) therapy approved for the consolidation treatment of B-ALL, regardless of MRD status. It is a pioneering immunotherapy that utilizes the body’s immune system to target and destroy cancer cells.

What are the new findings from recent clinical trials regarding Blincyto?

Recent trials, including the E1910 and 20120215 studies, have reaffirmed Blincyto’s efficacy in increasing overall survival and relapse-free survival rates in both adult and pediatric patients with B-ALL. These findings highlight its role in the consolidation phase of chemotherapy.

Is Blincyto available in Asia?

Yes, Blincyto injection is available in Asian countries such as Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.

How can I get Blincyto injection?

Urgent Meds can facilitate the supply of Blincyto (prescription medicine) to locations worldwide while adhering to legal requirements.

How does Blincyto fit into the current treatment landscape for B-ALL?

Blincyto’s approval for use in the consolidation phase represents a shift in the standard of care for B-ALL, potentially leading to deeper remissions and improved survival outcomes.

Where is Blincyto available in India?

Blincyto is available in India in cities including Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Bangalore, Pune, and others.